New Delhi – After securing permission from the Clinical Trials Regulator of India (CTRI), trials have been initiated by Baba Ramdev’s foundation Patanjali Ayurved.
Acharya Balkrishna, the CEO of Patanjali Ayurved Limited said, “It was not easy to get permission for conducting trials for drugs for coronavirus. The Indian Council of Medical Research (ICMR) also did not show interest in our medicine; therefore, we decided to register with the Clinical Trials Regulatory Authority of India and started clinical trials at one of the departments under Jaipur University. Since February, the Patanjali group had started treatment on corona affected patients. By March, Patanjali had successfully treated many patients, but this was not part of evidence-based clinical trials. We are required to go through trials to get our research registered as a cure for corona; therefore, we obtained necessary permissions. Our laboratories are excellent when compared to any other Ayurvedic establishments. We currently have 500 researchers, of which at least 100 of them are postdoctoral researchers”.
